All news

Russian health ministry registers Convacell anti-coronavirus vaccine

Convacell can be used to vaccinate adults aged between 18 and 60

MOSCOW, March 19. /TASS/. The Russian health ministry has registered the Convacell anti-coronavirus vaccine, developed by the St. Petersburg Research Institute of Vaccines and Serums under the Federal Medical-Biological Agency (FMBA) of Russia, according to the ministry’s register.

"Convacell, a subunit recombinant vaccine to prevent the coronavirus infection, caused by the SARS-CoV-2 virus. Date of ruling: 18.03.2022," the entry says.

The vaccine’s shelf life is six months, if stored in a dark place, in temperatures of between two and eight degrees Centigrade.

According to the medication package insert, published on Friday, Convacell can be used to vaccinate adults aged between 18 and 60. It is administered in two stages, with the interval of 21 days.

Contraindications to the use of the vaccine are pregnancy and breastfeeding, serious allergic reactions, acute infectious diseases and flare-ups of chronic conditions. It should be used with caution in patients suffering from cancer, chronic conditions and autoimmune diseases.

FMBA chief Veronika Skvortsova said earlier that the vaccine is unlikely to cause and allergic reaction and is well tolerated by patients.

In June 2021, preclinical studies of the vaccine were completed, proving its safety, immunogenicity and protective potential.